Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate 9.87% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Poor long term growth as Operating profit has grown by an annual rate 9.87% of over the last 5 years
3
Flat results in Dec 24
4
With ROE of 19.66%, it has a Very Expensive valuation with a 0.60 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.8%
0%
-7.8%
6 Months
-13.99%
0%
-13.99%
1 Year
-15.26%
0%
-15.26%
2 Years
-3.96%
0%
-3.96%
3 Years
-31.91%
0%
-31.91%
4 Years
35.19%
0%
35.19%
5 Years
17.3%
0%
17.3%
China Resources Pharmaceutical Group Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.98%
EBIT Growth (5y)
9.87%
EBIT to Interest (avg)
3.87
Debt to EBITDA (avg)
2.67
Net Debt to Equity (avg)
1.09
Sales to Capital Employed (avg)
1.87
Tax Ratio
23.92%
Dividend Payout Ratio
25.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.46%
ROE (avg)
16.20%
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
0.60
EV to EBIT
6.93
EV to EBITDA
5.37
EV to Capital Employed
0.81
EV to Sales
0.31
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
11.64%
ROE (Latest)
19.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
244,703.90
254,106.40
-3.70%
Operating Profit (PBDIT) excl Other Income
13,924.10
13,964.60
-0.29%
Interest
2,386.30
2,854.00
-16.39%
Exceptional Items
-1,365.30
-585.80
-133.07%
Consolidate Net Profit
7,775.00
7,843.30
-0.87%
Operating Profit Margin (Excl OI)
44.00%
42.60%
0.14%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -3.70% vs 7.31% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -0.87% vs 17.99% in Dec 2022
About China Resources Pharmaceutical Group Ltd. 
China Resources Pharmaceutical Group Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






